MAYMUN ÇİÇEĞİ, GEÇMİŞTEN GÜNÜMÜZE

Year 2022, Volume: 24 Issue: 2, 409 - 416, 31.08.2022

Ayşegül Tuna

https://doi.org/10.24938/kutfd.1135547

Abstract

Poxviridae ailesine ait zoonotik bir hastalık olan maymun çiçeği 1958 yılında maymunlardan izole edilmiştir. İnsanlarda çiçek hastalığına benzer bir klinik oluşturur. Enfekte hayvan ısırığı, vücut sıvıları ile temas ve damlacık yoluyla bulaş tipiktir. 2003 ve sonrasında özellikle ithalat ve turizm nedenli seyahat ile birçok ülkede salgınlara neden olmuştur. 2022 yılında görülen salgında ise bulaşın cinsel aktivite ile ilişkili olduğu düşünülmektedir. Çiçek aşısı ile bağışıklanmamış bireyler hastalık açısından risk grubunu oluşturmaktadır. İnkübasyon süresinin ortalama 6-13 gün olduğu kabul edilir. Ateş, lenfadenopati ve miyalji varlığı diğer döküntülü hastalıklardan ayırt edicidir. Ayırıcı tanıda numunelerin referans laboratuvara gönderilerek doğrulamasının yapılması şarttır. Şüphelenilen vakalar hakkında yerel halk sağlığı yetkililerine bilgi verilmesi gerekir. Destek tedavisi esastır. Özel hasta grupları için tekovirimat, brinsidofovir veya sidofovir gibi antiviral tedaviler halk sağlığı yetkilileri onayı ile başlanabilir. Ayırıcı tanı olarak düşünüldüğü her durumda tanı dışlanana kadar temas, damlacık ve solunum izolasyon önlemleri de uygulanmalıdır. Temas öncesi veya temas sonrası profilaksi için yine yerel halk sağlığı yetkilileri onayı ile çiçek aşısı uygulanabilir.

Keywords

maymun çiçeği, salgın, çiçek aşısı

Monkeypox: Past to Present

Abstract

Monkey pox, a zoonotic disease belonging to the Poxviridae family, was isolated from monkeys in 1958. It causes clinical findings similar to smallpox in humans. Transmission is typical through the bite of an infected animal, contact with bodily fluids and droplets. Since 2003, it caused epidemics in many countries, especially in import and tourism-based travel. In the epidemic in 2022, transmission is thought to be related to sexual activity. Individuals who are not immunized with smallpox vaccine constitute the risk group for the disease. The average incubation period is considered to be 6-13 days. The presence of fever, lymphadenopathy and myalgia are different from other diseases with rash. It is essential to confirm the differential diagnosis by sending the samples to the reference laboratory. Local public health authorities should be informed about suspected cases. Supportive treatment is essential. Antiviral treatments such as tecovirimate, brincidofovir or cidofovir may be used for specific patient groups with the approval of public health authorities. In any case considered as a differential diagnosis, contact, droplet and respiratory isolation precautions should also be applied until the diagnosis is excluded. Smallpox vaccine can be administered for pre/post-exposure prophylaxis, again with the approval of local public health authorities.

Keywords

monkeypox, outbreak, smallpox vaccine

References

• 1. Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005;41(12):1765-71.
• 2. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR et al. The changing epidemiology of human monkeypox—a potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.
• 3. Centers for Disease Control and Prevention. Erişim Tarihi: 20 Haziran 2022:https://www.cdc.gov/poxvirus/monkeypox/index.html.
• 4. Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1998;54(3):693-702.
• 5. Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR. 2003;52:642-6.
• 6. Centers for Disease Control and Prevention (CDC). Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003. MMWR. 2003;52:537-40.
• 7. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis. 2006;194 (6):773-80.
• 8. Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ. 2020;98(9):638-40.
• 9. World Health Organization. Multi-country monkeypox outbreak in non-endemic countries. Erişim Tarihi 20 Haziran 2022: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385.
• 10. Rimoin AW, Mulembakani PM, Johnston SC, Smith JOL, Kisalu NK, Kinkela TL et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010;107(37):16262-7. 11. United States Centers for Disease Control and Prevention. CDC and Texas Confirm Monkeypox In U.S. Traveler. Erişim Tarihi 21 Haziran 2022: https://www.cdc.gov/media/releases/2021/s0716-confirm-monkeypox.html.
• 12. Fleischauer AT, Kile JC, Davidson M, Fischer M, Karem KL, Teclaw R et al. Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis. 2005;40(5):689-94.
• 13. Minhaj FS, Ogale YP, Whitehill F, Schultz J, Foote M, Davidson W et al. Monkeypox Outbreak - Nine States, May 2022. MMWR. 2022;71(23):764-9.
• 14. European Centers for Disease Control. Monkeypox cases reported in UK and Portugal. Erişim tarihi: 21 Haziran 2022: https://www.ecdc.europa.eu/en/news-events/monkeypox-cases-reported-uk-and-portugal.
• 15. Vaughan A, Aarons E, Astbury J, Brooks T, Chand M, Fleeg P et al. Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018. Emerg Infect Dis. 2020;26(4):782-5.
• 16. Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis. 2005;41(12):1742-51.
• 17. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872-9.
• 18. Basgoz N, Brown CM, Smole SC, Madoff LC, Biddinger PD, Baugh JJ et al. Case 24-2022: a 31-year-old man with perianal and penile ulcers, rectal pain, and rash. N Engl J Med. 2022. doi: 10.1056/NEJMcpc2201244.
• 19. Olson VA, Laue T, Laker MT, Babkin IV, Drosten C, Shchelkunov SN et al. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol. 2004;42(5):1940-6.
• 20. Bayer-Garner IB. Monkeypox virus: histologic, immunohistochemical and electron-microscopic findings. J Cutan Pathol. 2005;32(1):28-34.
• 21. Karem KL, Reynolds M, Braden Z, Lou G, Bernard N, Patton J et al. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Vacc Immunology. 2005;12(7):867-72.
• 22. FDA approves the first drug with an indication for treatment of smallpox. Erişim tarihi: 21 Haziran 2022: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox.
• 23. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF et al. Clinical features and management of human monkeypox. Lancet Infect Dis. 2022. doi:10.1016/S1473-3099(22)00228-6.
• 24. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holy A et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 2006;439(7077):745-8.
• 25. US Food and Drug Administration: FDA approves drug to treat smallpox. Erişim tarihi: 21 Haziran 2022: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-treat-smallpox.
• 26. Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SC, Strelow LI et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med. 2005;11(9):1005-11.
• 27. US Food and Drug Administration. FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox. Erişim tarihi: 21 Haziran 2022: https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox
• 28. United States Centers for Disease Control and Prevention. Orthopoxvirus vaccine guidance for persons at risk for occupational Exposure. Erişim tarihi: 21 Haziran 2022: https://www.cdc.gov/poxvirus/occupational-exposures/orthop. oxvirus-vaccine-guidance.html
• 29. Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg Infect Dis. 2021;27(4):1007-14.
• 30. Jamieson DJ, Cono J, Richards CL, Treadwell TA. The role of the obstetrician-gynecologist in emerging infectious diseases: monkeypox and pregnancy. Obstet Gynecol. 2004;103(4):754-6.